WATERTOWN, Mass.--(BUSINESS WIRE)--Tectonic Therapeutic, Inc. (“Tectonic”) (NASDAQ: TECX), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs, today announced the completion of its previously announced merger with AVROBIO, Inc.

马萨诸塞州沃特敦市。-（商业新闻短讯）--Tectonic Therapy，Inc.（“Tectonic”）（纳斯达克：TECX），一家临床阶段生物技术公司，专注于发现和开发调节GPCR活性的治疗性蛋白质和抗体，今天宣布完成之前宣布的与AVROBIO，Inc.的合并。

('AVROBIO'). The combined company will operate under the name Tectonic Therapeutic, Inc., and its shares are expected to begin trading on the Nasdaq Global Market on June 21, 2024 under the ticker symbol 'TECX'..

。合并后的公司将以构造治疗公司的名义运营，其股票预计将于2024年6月21日在纳斯达克全球市场开始交易，股票代码为“TECX”。。

Concurrent with the merger, Tectonic completed a $130.7 million private placement with a syndicate of new and existing investors, including a major mutual fund, TAS Partners, 5AM Ventures, EcoR1 Capital, Polaris Partners, certain funds and accounts advised by Farallon Capital Management, Vida Ventures, the PagsGroup, and other undisclosed investors.

在合并的同时，大地构造与新的和现有的投资者组成的财团完成了1.307亿美元的私人配售，其中包括一家大型共同基金、TAS Partners、5AM Ventures、EcoR1 Capital、Polaris Partners、Farallon Capital Management、Vida Ventures、PagsGroup和其他未披露投资者提供的某些基金和账户。

Following these transactions, Tectonic’s cash, cash equivalents and investments of approximately $181 million at close, before payment of final transaction-related expenses, is expected to fund current operational plans into mid-2027..

在这些交易之后，在支付最终交易相关费用之前，大地构造的现金、现金等价物和投资约为1.81亿美元，预计将为2027年年中的当前运营计划提供资金。。

'It's an exciting time to be transitioning into a publicly-traded company. We expect to initiate a randomized Phase 2 clinical trial for our lead program, TX45, in Group 2 Pulmonary Hypertension in the setting of Left Heart Disease with Preserved Ejection Fraction in the second half of this year. Results from the ongoing Phase 1a clinical trial in this patient population are expected in mid-2024, to be followed by Phase 1b results expected in 2025 and results from the Phase 2 clinical trial expected in 2026.

“这是一个向上市公司转型的激动人心的时刻。我们预计在今年下半年为我们的主要项目TX45启动一项随机2期临床试验，该试验在第2组肺动脉高压中用于保留射血分数的左心疾病。。

We also expect to select a potential development candidate for our second program targeting a treatment for HHT, later this year, with the start of corresponding clinical studies anticipated to commence in the fourth quarter of 2025 or the first quarter of 2026,' said Alise Reicin, M.D., President and Chief Executive Officer of Tectonic..

大地构造总裁兼首席执行官Alise Reicin医学博士说：“我们还预计在今年晚些时候为针对HHT治疗的第二个项目选择一个潜在的发展候选者，相应的临床研究预计将在2025年第四季度或2026年第一季度开始。”。。

'We believe we are strongly positioned to enter the public markets at this time, with a solid financial foundation, investor syndicate and leadership team, and with several potential catalysts over the next two years, setting the stage for meaningful value creation. This transaction represents a major milestone in the evolution of Tectonic and in our efforts to bring innovative medicines to patients,” added Dr.

“我们相信，目前我们拥有坚实的财务基础、投资者财团和领导团队，并在未来两年内拥有多个潜在的催化剂，为有意义的价值创造奠定了基础，因此我们有能力进入公共市场。这项交易代表了构造演化和我们为患者带来创新药物的努力中的一个重要里程碑。

Reicin..

瑞辛。。。

Tectonic’s lead program, TX000045 (“TX45”), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Tectonic believes TX45’s pharmacological profile, the direct result of applying Tectonic’s protein engineering capabilities, has the potential to overcome the limitations that have impeded previous attempts to develop relaxin as a therapeutic protein..

大地构造的主要计划TX000045（“TX45”）是一种Fc松弛素融合分子，可激活RXFP1受体，即激素松弛素的GPCR靶标。大地构造认为，TX45的药理学特征是应用大地构造蛋白质工程能力的直接结果，有可能克服先前阻碍将松弛素开发为治疗性蛋白质的局限性。。

Tectonic’s second program addresses Hereditary Hemorrhagic Telangiectasia (“HHT”), the second-most common genetic bleeding disorder. It has been estimated that there are approximately 70,000 HHT patients in the United States. The target population for development is the 10-20% of HHT patients who are considered to have severe disease because of frequent bleeding, anemia, and in some cases, who require blood transfusions..

大地构造的第二个计划针对遗传性出血性毛细血管扩张症（“HHT”），这是第二常见的遗传性出血性疾病。据估计，美国约有70000名HHT患者。发展的目标人群是10-20%的HHT患者，这些患者由于频繁出血，贫血以及在某些情况下需要输血而被认为患有严重疾病。。

Transaction Details

交易详细信息

In connection with the closing of the merger, AVROBIO enacted a 1 for 12 reverse stock split of its common stock and issued a non-transferable contingent value right (a 'CVR') to AVROBIO shareholders of record immediately prior to the closing, which does not include the former holders of shares of Tectonic or the private placement investors.

关于合并的结束，AVROBIO对其普通股进行了12对1的反向股票分割，并在交割前向AVROBIO的在册股东发行了不可转让的或有价值权（“CVR”），其中不包括Structural的前股东或私募投资者。

Holders of a CVR will be entitled to receive certain cash payments from proceeds received by Tectonic, if any, related to the dispositions of AVROBIO’s pre-transaction legacy assets. Following the reverse stock split and based on the final exchange ratio of approximately 0.5344 shares of AVROBIO common stock for each share of Tectonic common stock, at the closing of the merger, there are approximately 15,371,780 shares of the combined company's common stock outstanding on a diluted basis, with prior AVROBIO stockholders owning approximately 24.8% on a diluted basis and prior Tectonic stockholders (including investors in the private placement) holding approximately 75.2% of the combined company's outstanding common stock on a diluted basis..

CVR持有人将有权从Structural收到的与AVROBIO交易前遗留资产处置相关的收益（如有）中获得一定的现金支付。在反向股票分割之后，根据AVROBIO普通股与构造普通股每股约0.5344股的最终交换率，在合并结束时，合并公司的普通股中约有15371780股在稀释基础上流通，之前的AVROBIO股东在稀释基础上持有约24.8%，之前的构造股东（包括私募投资者）在稀释基础上持有合并公司已发行普通股的约75.2%。。

Leerink Partners served as exclusive financial advisor to Tectonic and Cooley LLP served as legal counsel to Tectonic. Leerink Partners and TD Cowen acted as joint placement agents for Tectonic’s private placement. Piper Sandler acted as capital markets advisor to Tectonic. TD Cowen served as lead financial advisor to AVROBIO, Houlihan Lokey served as co-financial advisor to AVROBIO, and Goodwin Procter LLP served as legal counsel to AVROBIO..

Leerink Partners担任大地构造的独家财务顾问，Cooley LLP担任大地构造的法律顾问。Leerink Partners和TD Cowen担任Technotic私募的联合配售代理。派珀·桑德勒（Piper Sandler）担任《大地构造》的资本市场顾问。TD Cowen担任AVROBIO的首席财务顾问，Houlihan Lokey担任AVROBIO的联合财务顾问，Goodwin Procter LLP担任AVROBIO的法律顾问。。

About Tectonic

关于构造

Tectonic Therapeutic is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”). Leveraging its proprietary technology platform called GEODe™ (“GPCRs Engineered for Optimal Discovery”), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease.

构造治疗是一家生物技术公司，专注于发现和开发调节G蛋白偶联受体（“GPCR”）活性的治疗性蛋白质和抗体。利用其名为GEODe™的专有技术平台（“GPCR为最佳发现而设计”），Tectonic专注于开发生物药物，以克服GPCR靶向药物发现的现有挑战，并利用人体改变疾病进程。

Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow @TectonicTx on X (formerly Twitter) and LinkedIn..

大地构造专注于严重未满足医疗需求的领域，通常是治疗选择不佳或不存在的领域，因为这些领域的新药有可能改善患者的生活质量。大地构造公司总部位于马萨诸塞州沃特敦。欲了解更多信息，请访问www.tectonictx.com，并在X（以前的Twitter）和LinkedIn上关注@tectonictx。。

Forward-Looking Statements

前瞻性声明

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words.

本新闻稿包含1995年《私人证券诉讼改革法案》中“安全港”条款所指的“前瞻性声明”。除历史事实陈述外，本新闻稿中的所有陈述均为“前瞻性陈述”。这些陈述可以用“目标”、“预期”、“相信”、“可能”、“估计”、“预期”、“预测”、“目标”、“打算”、“可能”、“计划”、“可能”、“潜在”、“寻求”、“将要”等词语或类似词语的变体来识别，尽管并非所有前瞻性陈述都包含这些词语。

Forward-looking statements in this press release include, but are not limited to, statements regarding: the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of Tectonic’s product candidates, including the ongoing Phase 1a/b clinical trial for its lead program, TX45, in Group 2 Pulmonary Hypertension and initiation of Phase 2 clinical trial; candidate selection for Tectonic’s second program in HHT; market opportunity and Tectonic’s anticipated cash runway.

本新闻稿中的前瞻性声明包括但不限于以下声明：关于大地构造候选产品当前和未来临床前研究和临床试验的设计、目标、启动、时间安排、进展和结果，包括正在进行的第2组肺动脉高压领导项目TX45的1a/b期临床试验和第2阶段临床试验的启动；HHT大地构造第二个项目的候选人选择；市场机会和大地构造的预期现金跑道。

These forward-looking statements are based on Tectonic’s expectations and assumptions as of the date of this press release. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Tectonic’s control. Actual results and the timing of events could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (i) the ability of AVROBIO and Tectonic to integrate their businesses successfully and to achieve anticipated synergies; (ii) the possibi.

截至本新闻稿发布之日，这些前瞻性声明基于大地构造的预期和假设。前瞻性陈述受到许多风险和不确定性的影响，其中许多涉及构造无法控制的因素或情况。由于各种因素的影响，实际结果和事件发生的时间可能与任何前瞻性声明中包含的结果有很大不同，包括但不限于：（i）AVROBIO和Structural成功整合其业务并实现预期协同效应的能力；（ii）可能性。